These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 12722692)

  • 41. [Implementation of new Japanese GCP and the quality of clinical trials--from the standpoint of the pharmaceutical industry].
    Ebi O
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1883-91. PubMed ID: 9350232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Why multi-national clinical trials now?--Industry perspective].
    Miki S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):293-6. PubMed ID: 17301547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care.
    Hippe E; Westin J; Wislöff F
    Eur J Haematol; 2005 Mar; 74(3):185-93. PubMed ID: 15693787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disparities in gastric cancer chemotherapy between the East and West.
    Ohtsu A; Yoshida S; Saijo N
    J Clin Oncol; 2006 May; 24(14):2188-96. PubMed ID: 16682738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of cancer cooperative groups in Japan.
    Fukuda H
    Jpn J Clin Oncol; 2010 Sep; 40(9):881-90. PubMed ID: 20670961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Current problems of early phase clinical trials for new anticancer agents in Japan].
    Nakagawa K; Fukuoka M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):925-9. PubMed ID: 10897223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Seeking informed consent to cancer clinical trials; evaluating the efficacy of doctor communication skills training.
    Brown RF; Butow PN; Boyle F; Tattersall MH
    Psychooncology; 2007 Jun; 16(6):507-16. PubMed ID: 16986176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current issues and perspectives in Japan Clinical Oncology Group].
    Fukuda H; Niimi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):204-11. PubMed ID: 9987520
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Impact of rapid advancement of international standardization on technical requirements for new drug registration].
    Kurokawa T
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):509-16. PubMed ID: 8678507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The history and future of the Urologic Oncology Study Group (UOSG) of the Japan Clinical Oncology Group (JCOG).
    Tobisu K
    Jpn J Clin Oncol; 2012 May; 42(5):363-7. PubMed ID: 22450928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
    LoRusso PM; Anderson AB; Boerner SA; Averbuch SD
    Clin Cancer Res; 2010 Dec; 16(24):5956-62. PubMed ID: 21169248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Problems of protocol practice in Japan.
    Nose Y; Akazawa K; Hayashi Y; Shimada M; Watanabe Y; Higashi H; Moriguchi S; Fujisawa K
    Jpn Hosp; 1991 Jul; 10():19-24. PubMed ID: 10111640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Japan Clinical Oncology Group for cooperative cancer clinical trials and role of the statistical center in the management of cancer clinical trials].
    Shimoyama M; Tajima K
    Gan To Kagaku Ryoho; 1993 Dec; 20(16):2507-18. PubMed ID: 8279849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it.
    Gwede CK; Johnson DJ; Daniels SS; Trotti A
    J Oncol Manag; 2002; 11(2):15-21. PubMed ID: 11989815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.